Tarsus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	112.72	94.82	224.95	71.66	171.33	168.13
Short-Term Investments	289.11	196.56	2.5	145.37	0.48	-
Cash & Short-Term Investments	401.84	291.38	227.44	217.03	171.82	168.13
Cash Growth	26.78%	28.11%	4.80%	26.31%	2.19%	190.12%
Accounts Receivable	72.62	46.76	16.62	-	-	-
Other Receivables	1.72	1.3	1.09	3.58	0.09	0.02
Receivables	74.34	48.06	17.71	3.58	0.09	0.02
Inventory	3.84	2.62	3.11	-	-	-
Prepaid Expenses	21.7	14.65	7.87	4.77	4.05	2.49
Restricted Cash	-	-	-	-	-	0.02
Total Current Assets	501.7	356.71	256.13	225.38	175.95	170.66
Property, Plant & Equipment	15.98	2.87	3.35	1.53	1.83	1.24
Long-Term Investments	3	3	0.86	0.48	0.66	-
Other Intangible Assets	7.61	8.33	3.87	-	-	-
Other Long-Term Assets	6.27	6.09	1.29	0.48	0.46	0.08
Total Assets	534.56	376.99	265.49	227.86	178.91	171.97
Accounts Payable	40.64	27.74	17.77	5.5	2.86	2.24
Accrued Expenses	19.98	19.14	13.9	9.21	7.26	2.87
Current Portion of Leases	0.08	0.61	0.4	0.72	0.61	0.28
Current Income Taxes Payable	-	-	-	-	0.06	-
Current Unearned Revenue	-	-	-	-	0.7	-
Other Current Liabilities	56.35	33.12	4.87	-	-	-
Total Current Liabilities	117.05	80.61	36.94	15.43	11.48	5.39
Long-Term Debt	72.28	71.85	29.82	19.43	-	-
Long-Term Leases	10.15	-	-	-	0.59	0.55
Other Long-Term Liabilities	-	-	1.75	0.1	0.11	0.06
Total Liabilities	199.48	152.46	68.5	34.96	12.18	5.99
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	753.04	584.56	441.64	301.73	213.4	198.82
Retained Earnings	-418.26	-360.21	-244.66	-108.76	-46.67	-32.85
Comprehensive Income & Other	0.29	0.18	-0	-0.07	-	-
Total Common Equity	335.08	224.53	196.99	192.9	166.73	165.98
Shareholders' Equity	335.08	224.53	196.99	192.9	166.73	165.98
Total Liabilities & Equity	534.56	376.99	265.49	227.86	178.91	171.97
Total Debt	82.51	72.45	30.22	20.16	1.19	0.83
Net Cash (Debt)	319.33	218.92	197.23	196.87	170.62	167.3
Net Cash Growth	31.21%	11.00%	0.18%	15.38%	1.99%	189.50%
Net Cash Per Share	7.84	5.82	6.71	8.00	8.30	26.95
Filing Date Shares Outstanding	42.45	38.38	34.22	26.73	20.71	20.32
Total Common Shares Outstanding	42.45	38.35	34.21	26.73	20.7	20.32
Working Capital	384.65	276.09	219.2	209.95	164.47	165.27
Book Value Per Share	7.89	5.85	5.76	7.22	8.06	8.17
Tangible Book Value	327.48	216.21	193.12	192.9	166.73	165.98
Tangible Book Value Per Share	7.71	5.64	5.64	7.22	8.06	8.17
Machinery	4.49	3.5	2.08	1.08	0.85	0.54
Leasehold Improvements	3.88	0.79	0.68	0.43	0.13	0.14

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q